UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 613, ~~2014~~2015 (January 512, ~~2014~~2015)

CANADIAN CANNABIS CORP.

(Exact name of registrant as specified in its charter)

Delaware

000-54915

45-3327444

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 Rutherford Road South

Brampton, Ontario, Canada

L6W 2J2

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (866) 790-3324

____________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

FORWARD-LOOKING STATEMENTS

There are statements in this Current Report on Form 8-K that are not historical facts. These “forward-looking statements” can be identified by use of terminology such as “believe,” “may,” “anticipate,” “should,” “intend,” “~~plan,” “~~will,” “~~expect,” “~~estimate,” “project,” and similar expressions. You should be aware that these forward-looking statements are subject to risks and uncertainties that are beyond our control. Although management believes that the assumptions underlying the forward looking statements included in this Current Report are reasonable, they do not guarantee our future performance, and actual results could differ from those contemplated by these forward looking statements. The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. In the light of these risks and uncertainties, there can be no assurance that the results and events contemplated by the forward-looking statements contained in this Current Report will in fact transpire. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise any forward-looking statements. ~~The following discussion should be read in conjunction with the Company’s financial statements and pro forma financial statements and the related notes filed with this Form 8-K/A.~~

As used in this Current Report and unless otherwise indicated, the terms “we”, “us”, “our”, and the “Company” refer to Canadian Cannabis Corp.

Item 85.0102 Departure ~~Other~~of ~~Events~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnElection ~~January 5, 2015, we entered into a Letter~~ of ~~Intent (the “LOI”) with Novo Healthnet Limited, an Ontario limited company (“Novo”) and ALMC-ASAP Holdings Inc. (“AAH”) pursuant to which we intend to negotiate and enter into~~ a ~~definitive~~ ~~agreement~~New (the “Definitive Agreement”) to acquire from AAH all of the stock of Novo held by AAH (the “Novo Stock”), constituting sixty-one percent (61%) of all of the issued and outstanding stock of Novo. Pursuant to the LOI, in connection with the closing of the acquisition of the Novo Stock, we also expect to obtain rights to appoint three (3) directors to the Novo board of directors and two (2) officers to Novo, one in an operational role and the other as Secretary/Treasurer. In consideration of the Novo Stock and the Novo director and officer appointment rights, we intend to issue two million (2,000,000) shares of common stock of the Company at closing (the “Transaction”).Director

~~Novo and AAH must each~~On ~~satisfy~~January ~~our~~12 ~~due~~2015, ~~diligence~~Richard ~~investigation~~Wachsberg ~~and~~was ~~meet~~appointed ~~other~~as ~~closing~~a ~~conditions~~director ~~customary to similar transactions prior to the closing~~ of ~~the~~Canadian ~~Transaction,~~Cannabis ~~the~~Corp. ~~details~~by ofa ~~which~~majority ~~remain~~vote ~~subject to final documentation~~ of the ~~Definitive Agreement. In addition, prior~~remaining todirectors ~~the closing~~ of the ~~Transaction,~~Company. ~~Novo~~Mr. isWachsberg ~~required~~will toinitially ~~discharge~~serve ~~certain debt currently carried~~ on ~~its balance sheet in~~ the ~~approximate amount~~Executive Committee of ~~$3,000,000. Should~~ the ~~Transaction close as planned, the~~ Company ~~will~~board ~~become the majority shareholder~~ of ~~Novo~~directors.

The ~~LOI~~Company ~~contains~~intends ~~additional~~to ~~provisions~~compensate ~~customary~~Mr. toWachsberg ~~transactions~~for his services on the board in the amount of CAD $31,250 (approximately USD $26,118) per quarter. As of the filing of this ~~type~~Current Report on Form 8-K, the details of Mr. Wachsberg’s compensation remain subject to finalizing and documentation of same.

WeAdditionally, ~~expect~~Mr. ~~that~~Wachsberg ~~the~~owns ~~issuance~~100,000 of shares of the Company’s common stock, representing less than 1% ownership interest in ~~connection~~the ~~with~~Company. Mr. Wachsberg also owns 500,000 warrant shares, which are exercisable for an additional 500,000 shares of the ~~Transaction~~Company’s common ~~will~~stock, and has the option to acquire up to an additional 400,000 warrant shares, which would be ~~exempt~~exercisable ~~from~~for ~~registration~~up to an ~~under~~additional ~~Section~~400,000 ~~4(2)~~shares of the ~~Securities~~Company’s ~~Act~~common stock.

Novo operates and partners with clinics offering multi-disciplinary rehabilitation solutions for patients, eldercare health and wellness services for seniors, and medical assessments, across Canada, and currently serves approximately 28,100 individuals.

The foregoing summaries of the Transaction and LOI are not complete and are qualified in their entirety by reference to the complete text of the LOI, which is attached hereto as Exhibits 10.1, and remain subject to the completion of due diligence, execution of the Definitive Agreement, and closing of the Transaction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Description

10.1 Letter of Intent, by and among Canada Cannabis Corp., Novo Healthnet Limited, and ALMC-ASAP Holdings, Inc., executed as of January 5, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~Canadian Cannabis Corp.~~	Canadian Cannabis Corp.
	~~(Registrant)~~	(Registrant)
Date: January 6, 2015	By:	/S/ Benjamin Ward
Date: January 13, 2015		By:	/S/ Benjamin Ward
		~~Benjamin Ward CEO, President, and Director~~	Benjamin Ward CEO, President, and Director

Filing Compare · CANADIAN CANNABIS CORP.